enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Stock Information for enVVeno Medical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About enVVeno Medical Corporation

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
enVVeno Medical Announces Reverse Stock Split
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.